Intrabeam radiotherapy system for adjuvant treatment of early breast cancer

  • Technology appraisal guidance
  • TA501
  • Published: 
Download guidance (PDF)

1 Recommendations

1.1 The Intrabeam radiotherapy system is not recommended for routine commissioning for adjuvant treatment of early invasive breast cancer during breast-conserving surgical removal of the tumour.

1.2 Use of the Intrabeam radiotherapy system is recommended only using machines that are already available and in conjunction with NHS England specified clinical governance, data collection and submission arrangements.

1.3 The procedure should only be carried out by clinicians with specific training in the use of the Intrabeam radiotherapy system.

1.4 Patient selection for Intrabeam radiotherapy should be done by a multidisciplinary team experienced in the management of early invasive breast cancer, which includes both breast surgeons and clinical oncologists.

1.5 Clinicians wishing to undertake Intrabeam radiotherapy should take the following actions:

  • Inform the clinical governance leads in their NHS trusts.

  • Ensure that patients understand the uncertainties about the procedure and inform them about alternative treatment options.

  • Provide patients with NICE's written information on the evidence of the risks and benefits of the range of treatment options available as an aid to shared decision-making.